More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to improve treatment options and patient outcomes. Major pharmaceutical firms like Pfizer, GSK, and United Therapeutics are leading innovations with novel therapies targeting different biological pathways. This surge in clinical research highlights a growing focus on addressing unmet medical needs and advancing PAH treatment globally.
In May 2026, despite overall high market valuations, five stocks trading under $30 stand out for their strong financial health and growth prospects. Pfizer offers a 6.68% dividend yield and growth from its non-COVID portfolio and obesity pipeline, wh...
Stocks priced under $30 often get overlooked, but Pfizer and Nu Holdings stand out with solid balance sheets and growth potential. Pfizer, a global biopharma giant, trades around $25 with a strong dividend yield and promising pipeline despite some re...
Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent F...
Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton for their strong cash flow, pricing power, and stable margins amid ongoing inflation. Pfizer offers a 6.66% dividend yield and growth potential as COVID impacts fade, trading at...
